biopharma-reporter1d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
biopharma-reporter1d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for its biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.
biopharma-reporter1d
Synaffix and BigHat Biosciences collaborate to develop AI-designed ADC
The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...
biopharma-reporter5d
Top 10 rare disease pharma sees 10.4% rise in therapy start
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% ...
biopharma-reporter5d
Abzena’s advanced drug development showcased at CPHI Milan
At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...
biopharma-reporter6d
All news articles for November 2024
A new case study released by AllazoHealth reveals that a leading rare disease pharmaceutical company achieved a 10.4% increase in therapy initiation, driven by AI-enabled patient outreach and ...
biopharma-reporter6d
Abzena announces major expansion of its biologics manufacturing facility
The U.S. contract development and manufacturing organization (CDMO) Abzena announced yesterday that it has significantly ...